# US 10,945,965 B2 · Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,945,965 B2
- Document ID: US10945965B2
- Status: Granted
- Kind: B2
- Application number: 14/364,859
- Filed: 2012-12-17
- Published: 2014-11-13
- Granted: 2021-03-16
- Earliest claimed: 2011-12-16
- Assignees: Nanobiotix
- Applicants: Nanobiotix
- Inventors: Agnes Pottier; Laurent Levy; Marie-Edith Meyre
- Web page: https://patentgrep.com/patent/US10945965B2

## CPC

- A61K 9/5115: {Inorganic compounds}
- A61K 9/0009: {involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis}
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 33/242: Gold; Compounds thereof
- A61K 33/244: Lanthanides; Compounds thereof (medicinal preparations containing radioactive lanthanides for use in therapy or testing in vivo A61K51/00)
- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61K 41/0052: {Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy}
- A61K 49/00: Preparations for testing in vivo
- A61K 49/04: X-ray contrast preparations
- A61K 51/1244: {microparticles or nanoparticles, e.g. polymeric nanoparticles}
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K 2123/00: Preparations for testing in vivo
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with a hafnium oxide material or embedded therein. When compared to existing products, these nanoparticles offer a remarkable benefit over risk ratio. Specifically, these nanoparticles potentiate the efficiency of known metallic nanoparticles. Indeed, they retain the metal's intrinsic properties and are now in addition safely usable in a mammal, in particular in a human being. The invention also relates to methods for producing said nanoparticles, to compositions containing same, and to uses thereof.

## Claims

### Claim 1

A method of identifying or destroying a target cell in a mammal comprising administering a non-radioactive nanoparticle to a mammal and exposing said mammal to a radiation source, wherein the non-radioactive nanoparticle consists of a metal selected from gold (Au), silver (Ag), platinum (Pt), palladium (Pd), tin (Sn), tantalum (Ta), ytterbium (Yb), zirconium (Zr), hafnium (Hf), terbium (Tb), thulium (Tm), cerium (Ce), dysprosium (Dy), erbium (Er), europium (Eu), holmium (Ho), iron (Fe), lanthanum (La), neodymium (Nd), praseodymium (Pr), lutetium (Lu) and mixtures thereof that is fully covered with a hafnium oxide material or embedded therein and the radiation source is ionizing radiation.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said target cell is a tumor cell, a stenosing cell or an immune system cell.

### Claim 3 (depends on 2)

The method according to claim 2, wherein said method comprises the application of a radiation source providing ionizing radiation in an amount and energy that destroys said target cell.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the metal is gold (Au).

### Claim 5 (depends on 1)

The method according to claim 1, wherein the metal is platinum (Pt).

### Claim 6 (depends on 1)

The method according to claim 1, wherein the metal is tantalum (Ta).

### Claim 7 (depends on 1)

The method according to claim 1, wherein the metal is hafnium (Hf).

### Claim 8 (depends on 1)

The method according to claim 1, wherein the metal is zirconium (Zr).

### Claim 9 (depends on 1)

The method according to claim 1, wherein the metal is iron (Fe).